Hillhouse HCare 2020 Global Health Industry Summit Prospectus

At a time when the COVID-19 pandemic is ravaging the globe and the value of the medical and broader health industry has become increasingly prominent, it is imperative to accelerate biotechnological innovation, enhance healthcare standards, and expedite the development of the broader health sector. Against this backdrop, the announcement of the “Hillhouse HCare 2020 Global Health Industry Summit” has drawn widespread attention from the healthcare industry.

It is reported that the summit aims to create the largest and most information-rich medical investment event in the healthcare industry, which will be fully presented through online live streaming from August 6th to August 10th. Clinical experts from top global hospitals, innovators in drug research and development, policymakers, hospital administrators, industry researchers, top investors, and entrepreneurs will gather here to share the world's most cutting-edge medical and pharmaceutical R&D technologies, exchange the most advanced management concepts and practices between China and abroad, and discuss the most pressing issues currently facing the healthcare industry.

The Hillhouse HCare Summit will span five days, featuring one main forum and 15 thematic sub-forums. Over 100 speakers from Asia, the Americas, and Europe will deliver 16 live broadcasts and 40 lectures. Additionally, more than 600 industry leaders, over 1,000 healthcare and pharmaceutical companies, and upwards of 1,500 investment institutions are expected to attend this prestigious event.

Based on the sub-forum agenda, participating guests will primarily engage in dialogue and exchange on the most cutting-edge directions and latest innovative achievements in the global healthcare industry, including: progress in the R&D of global COVID-19 vaccines and therapeutic antibodies; frontiers and advances in cell therapy; innovation in orphan drug R&D and market access; innovative practices in clinical research; opportunities and challenges in the field of gene therapy; the expansion of RNA and mRNA therapies from rare diseases to broader indications; and the clinical application of cardiovascular interventional devices and medical technologies.

The Mayo Clinic China Medical Summit is Mayo Clinic’s premier annual event, featuring the highest level of participation and the largest number of experts. This year, more than 15 distinguished guests took part, covering nine major thematic forums. Dialogues were conducted on some of the most common clinical topics, including personalized medicine as the next generation of healthcare, establishing sustainable patient management systems, building breast cancer prevention and treatment frameworks, new approaches to respiratory disease prevention and control along with population health management, healthcare big data and artificial intelligence, and healthcare quality and safety management.

So the question arises: with so many lectures, which ones are must-see highlights?

Amid the global ravages of the COVID-19 pandemic, worldwide attention has focused on the progress of COVID-19 vaccine development. At this summit, all vaccine companies invested by Hillhouse were present to share their R&D journeys and the latest advancements in COVID-19 vaccines.

The Cell Therapy Sub-Forum showcased the most cutting-edge technological advancements in current cell therapies. The summit invited Rick Klausner, Founder and CEO of Lyell Immunopharma, a global leader in cell therapy; David Chang, Co-Founder and CEO of Allogene; and Fan Xiaohu, Founder of Legend Biotech, a leading Chinese cell therapy company.

The RNA and mRNA Therapeutics Sub-Forum has invited Moderna, currently the most sought-after mRNA therapeutics company in the United States. Stéphane Bancel, the company’s Chief Executive Officer, will not only share the latest frontier developments in mRNA therapeutics but also recount the research and development journey of the world’s first mRNA-based COVID-19 vaccine.

This forum will showcase the latest technological advancements in interventional therapy for cardiovascular diseases. Previously, Hillhouse’s investment in MicroPort CardioFlow, a subsidiary of Hong Kong-listed MicroPort Scientific, demonstrated top-tier investors’ confidence in cardiovascular interventional treatments. This Cardiovascular Intervention Forum will present the field’s in-depth development trajectory and clinical progress.

Scan the QR code to register for the summit now,Note: Mentioning VCBeat can increase the likelihood of approval during backend review.。